Search results: (10000)
News IPFchecker Project Helps Detect Patients with Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis is a serious progressive disease of the lung tissue of unclear etiology. Highly effective antifibrotic therapy is used in treatment, which can significantly prolong the lives of patients. However, timely detection of the disease is necessary for treatment success. For this purpose, the IPFchecker web application has been created, which helps radiologists and pulmonologists with more accurate diagnosis and timely detection of the disease.
News From Biomarker Testing to NSCLC Treatment Selection
During a satellite symposium at this year's European Lung Cancer Congress (ELCC 2022), Prof. Martin Reck from the Department of Thoracic Oncology at the hospital in Grosshansdorf, Germany, discussed precision medicine in the treatment of non-small cell lung cancer (NSCLC). We have selected an overview of advancements in next-generation sequencing from his presentation for you.
News Teriflunomide in the Treatment of RRMS: The Best Working Drug Is the One That the Patient Actually Takes
Teriflunomide is an oral disease-modifying drug (DMD) used in the therapy of relapsing-remitting multiple sclerosis (RRMS). The authors of the cited American study assessed adherence to this treatment and subsequently the effect of adherence on the occurrence of RRMS relapses and the utilization of healthcare services during the first year following the initial prescription of teriflunomide.
News Idiopathic Pulmonary Fibrosis: Can This Disease Be Named More Precisely?
Much about idiopathic pulmonary fibrosis (IPF) is still unknown. Some experts would like to reclassify this disease. What classification options are available? What would a focus on the "progressive fibrotic phenotype" in research mean? And what would a change in classification mean for patients?
News Patient with a History of DOAC Usage in Neurological ICU with Stroke – Case Study
How should we approach patients with a stroke who are taking direct oral anticoagulants (DOACs) and correctly assess the situation? When should we administer the available antidote according to guidelines? The following case study from the Regional Hospital Liberec illustrates this increasingly common situation.
News Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome
A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.
News Cenobamate in the Therapy of Pharmacoresistant Epilepsy in a Warfarinized Patient – A Case Study
A case study from Czech practice presents a patient with pharmacoresistant epilepsy and concurrent warfarin medication for heart valve replacement, where the INR value remained within the cardiologist’s recommended range without further adjustments to anticoagulant therapy during combined antiepileptic therapy with cenobamate (CNB) under the recommended dose titration.
News Current Recommendations of the American Society of Hematology for the Prevention of Thromboembolic Disease and Duration of Prophylaxis in Patients Undergoing Major Surgery
At the end of 2019, new recommendations were published by the American Society of Hematology (ASH) for the prevention of thromboembolic disease (VTE) in hospitalized patients. The new guidelines also addressed the duration of VTE prophylaxis in patients undergoing major surgical procedures.
News Lorlatinib in a Patient with Meningeal Carcinomatosis – Case Report
The prognosis of patients with meningeal carcinomatosis is unfavorable. The following case report demonstrates how a targeted mechanism of action and optimal drug penetration into the central nervous system (CNS) can not only quickly relieve patients from neurological problems associated with meningeal infiltration, but also prolong their survival.
News Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis
Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and 17F for the treatment of moderate to severe plaque psoriasis in adults for whom systemic therapy is indicated. The phase III BE SURE clinical trial focused on comparing the efficacy and safety of bimekizumab and the tumor necrosis factor-alpha (TNF-α) inhibitor adalimumab, which currently serves as one of the mainstays of systemic therapy.
News Increase in Thyroid Cancer Incidence Due to the Coronavirus Pandemic?
According to available data, COVID-19 disease does not worsen the course of thyroid cancer. However, the restriction of medical care during the pandemic is associated with concern about an increase in the incidence of this malignant disease and the associated morbidity and mortality.
News Summary of Czech Recommendations for the Diagnosis and Treatment of Schizophrenia in Children and Adolescents 2022
In June 2022, the Psychiatric Society of the Czech Medical Association JEP updated its recommendations for the diagnosis and treatment of schizophrenia in children and adolescents. This is the first online version, which will allow for faster implementation of new findings important for clinical practice and decision-making by state institutions. We bring you a summary of the key points of these recommendations.
News Ocrelizumab in the treatment of multiple sclerosis in real-world practice – a systematic review of published studies
In controlled study programs, ocrelizumab has demonstrated beneficial effects on improving clinical parameters in patients with multiple sclerosis, such as the annual relapse rate or confirmed disability progression. However, to get a complete picture of its clinical benefit, real-world evidence in a broad patient population is also needed. A systematic review of real-world clinical practice studies with ocrelizumab, published in March 2023, demonstrates its benefits in patients with relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in terms of relapse frequency, disease activity on MRI, disability, absence of disease activity (NEDA), and quality of life.
News Current Options and Prospects for Effective Antiemetic Treatment in an Effort to Increase Adherence of Oncological Patients to Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) is strongly associated with treatment in the minds of many oncology patients, and its occurrence is rated as one of the most dreaded and stressful complications. For most patients, adherence to recommendations for antiemetic prophylaxis can successfully prevent the occurrence of CINV. A review article published last year by an international team of authors in the journal Future Oncology provides an overview of the current spectrum of options in CINV prophylaxis, focusing on the first combined preparation in this indication, containing the active substances netupitant and palonosetron.
News Why Do Women in the USA Receive Indicated Statin Therapy Less and in Lower Doses Than Men?
Statin use has been proven to reduce the risk of cardiovascular diseases in both men and women. However, women in the USA who are indicated for this treatment have historically taken it less frequently and in lower doses than men. The current status and possible causes were investigated by the study presented below.
News Reasons for Nonadherence to Statin Therapy - Survey Results Among Patients
Adherence to statin therapy remains suboptimal despite its proven benefits in reducing cardiovascular risk in individuals with dyslipidemia. Recently published survey results conducted among patients prescribed statins have identified barriers preventing proper adherence to this treatment.
News Hodgkin Lymphoma in a Summary of News from Post-ASH 2021
Dr. Anna Suredová from the Clinical Hematology Department of the Catalonian Oncology Institute in Barcelona, newly elected president of the European Society for Bone Marrow Transplantation (EBMT), also remotely participated in this year's Prague Hematology Days (PHD 2022). In her lecture, she presented an overview of highlights from 4 clinical studies regarding Hodgkin lymphoma (HL) presented during the Post-ASH 2021 meeting.
News Parenteral Nutrition as Part of Cancer Patient Treatment
Malnutrition represents a potentially serious complication for cancer patients. If it is not possible to meet the nutritional demands of the body through the enteral route, parenteral nutrition must be initiated. A doctor will recommend it in situations where the patient is at risk from the consequences of malnutrition. Up to 45% of these patients struggle with at least a 10% loss of their body weight.
News EHL preparations have the potential to change the quality of life for people with hemophilia
Within the therapeutic modalities for hemophilia, the current era offers a number of preparations. Newer extended half-life (EHL) replacement therapies can provide hemophiliacs with better protection against bleeding and allow for greater physical activity.
News Frequent Nausea During Chemotherapy Despite Antiemetic Prophylaxis
Current clinical research has focused on vomiting as a primary issue in the occurrence of CINV (chemotherapy-induced nausea and vomiting) and, using recommended antiemetic prophylaxis, this problem has been relatively well managed. However, the incidence and impact of nausea are underreported. We present the results of an observational study that evaluated the incidence of nausea in patients undergoing chemotherapy.